Diabetologia:强化血糖控制对糖尿病视网膜病变有双向影响

2014-03-14 desperado-c 丁香园

临床试验表明高血糖对糖尿病患者微血管并发症发生和发展有不利影响,因此,当前血糖控制中仍有糖尿病微血管并发症的基础治疗。同时,良好的血糖控制已被证明可降低新诊断2型糖尿病患者糖尿病视网膜病变的进展。然而,在病程长、而血糖控制欠佳的2型糖尿病患者中,这方面的研究数据较少。 为此,来自美国Jr VA医院的Azad教授及其团队进行了一项研究,探讨血糖控制欠佳的糖尿病患者中,强化血糖控制(INT)

临床试验表明高血糖对糖尿病患者微血管并发症发生和发展有不利影响,因此,当前血糖控制中仍有糖尿病微血管并发症的基础治疗。同时,良好的血糖控制已被证明可降低新诊断2型糖尿病患者糖尿病视网膜病变的进展。然而,在病程长、而血糖控制欠佳的2型糖尿病患者中,这方面的研究数据较少。【原文下载】

为此,来自美国Jr VA医院的Azad教授及其团队进行了一项研究,探讨血糖控制欠佳的糖尿病患者中,强化血糖控制(INT)和较高的血浆C肽水平是否与良好的视力结局有关。该研究结果在线发表在2014年03月06日的Diabetologia杂志上。

研究者在退伍军人糖尿病研究(VADT)的1791例受试者中选取了其中的858例,通过7个象限立体眼底照相对患者进行网膜病变的发生率和进展分级评估,评估分为在试验初期和试验5年后开展。

该研究结果表明,在校正所有协变量后,基线HbA1c每增加1%,糖尿病视网膜病变进展风险增加30%。在整个队列中,INT分组和年龄与糖尿病视网膜病变之间均无独立相关。然而,INT与年龄之间有双相作用。在年龄≤55岁的受试者中,INT可降低糖尿病视网膜病变的发生率,但在年龄≥70岁的受试者中,INT可增加糖尿病视网膜病变的发生率。

基线C肽水平每增加1pmol/ml, 糖尿病视网膜病变的发生率下降67.2%。同时基线C肽水平也是糖尿病视网膜病变进展的一个独立负风险因素,基线C肽水平每增加1pmol/ml,糖尿病视网膜病变进展的风险下降47%。

该研究提示,基线血糖控制差与糖尿病视网膜病变进展的风险增加相关。在年轻患者中,INT与糖尿病视网膜病变发生率下降相关,但在老年患者,INT与糖尿病视网膜病变风险增加有关。基线较高的C肽水平与糖尿病视网膜病变发生率和进展风险下降相关。

原始出处:

Azad N1, Agrawal L, Emanuele NV, Klein R, Bahn GD, Reaven P; and The VADT Study Group.Association of blood glucose control and pancreatic reserve with diabetic retinopathy in the Veterans Affairs Diabetes Trial (VADT).Diabetologia. 2014 Mar 6. 【原文下载】


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759420, encodeId=39091e5942003, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 13 15:14:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636834, encodeId=dc3b1636834a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 23 05:14:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041969, encodeId=15c32041969fa, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Nov 29 03:14:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269791, encodeId=22641269e9146, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272903, encodeId=2e4c12e29034f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413859, encodeId=f5491413859ba, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2014-06-13 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759420, encodeId=39091e5942003, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 13 15:14:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636834, encodeId=dc3b1636834a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 23 05:14:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041969, encodeId=15c32041969fa, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Nov 29 03:14:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269791, encodeId=22641269e9146, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272903, encodeId=2e4c12e29034f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413859, encodeId=f5491413859ba, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759420, encodeId=39091e5942003, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 13 15:14:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636834, encodeId=dc3b1636834a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 23 05:14:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041969, encodeId=15c32041969fa, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Nov 29 03:14:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269791, encodeId=22641269e9146, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272903, encodeId=2e4c12e29034f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413859, encodeId=f5491413859ba, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759420, encodeId=39091e5942003, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 13 15:14:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636834, encodeId=dc3b1636834a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 23 05:14:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041969, encodeId=15c32041969fa, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Nov 29 03:14:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269791, encodeId=22641269e9146, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272903, encodeId=2e4c12e29034f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413859, encodeId=f5491413859ba, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
    2014-03-16 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759420, encodeId=39091e5942003, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 13 15:14:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636834, encodeId=dc3b1636834a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 23 05:14:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041969, encodeId=15c32041969fa, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Nov 29 03:14:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269791, encodeId=22641269e9146, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272903, encodeId=2e4c12e29034f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413859, encodeId=f5491413859ba, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759420, encodeId=39091e5942003, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jun 13 15:14:00 CST 2014, time=2014-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636834, encodeId=dc3b1636834a3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 23 05:14:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041969, encodeId=15c32041969fa, content=<a href='/topic/show?id=85055014226' target=_blank style='color:#2F92EE;'>#强化血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50142, encryptionId=85055014226, topicName=强化血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sat Nov 29 03:14:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269791, encodeId=22641269e9146, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272903, encodeId=2e4c12e29034f, content=<a href='/topic/show?id=2f468983351' target=_blank style='color:#2F92EE;'>#血糖控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89833, encryptionId=2f468983351, topicName=血糖控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef84111, createdName=whlxd, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413859, encodeId=f5491413859ba, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Mar 16 02:14:00 CST 2014, time=2014-03-16, status=1, ipAttribution=)]

相关资讯

Diabetes Care:微动脉瘤更替预测临床意义黄斑水肿

  葡萄牙学者的一项研究表明,在伴有非增殖性糖尿病视网膜病变(NPDR)的糖尿病患者中,微动脉瘤更替可预测具临床意义黄斑水肿(CSME)形成。论文于2012年11月30日在线发表于《糖尿病护理》(Diabetes Care)。   此项前瞻性、单中心、观察性研究共纳入410例伴NPDR的糖尿病患者。受试者既往均未接受激光治疗,并接受2年随访或至CSME形成。在基线、6个月和最后访视(2

OPHTHALMOLOGY:雷珠单抗后早期或后期激光治疗的比较

       11月《眼科学》Ophthalmology发表的一篇文章提到:糖尿病视网膜病变临床研究网络的 3 年结果表明,与后期(至少 24 周以后)激光治疗相比,糖尿病性黄斑水肿(DME) 中央凹受累视力下降的患者接受玻璃体腔注射 ranibizumab 后,早期(注射后7到10天)局灶/格栅样激光的视力恢复效果并不优于后期激光治疗,

Diabetes Care;肾病增高糖尿病视网膜病变风险

     非增生性糖尿病视网膜病和视网膜出血       增生性糖尿病视网膜病和新血管    2012年12月28日在线发表于《糖尿病护理》的一项研究表明,血糖控制、眼部以外并发症(肾病、未愈合溃疡)与糖尿病视网膜病变风险增高相关。视网膜病变进展风险评分可帮助临床医生对糖尿病眼底病变高风险患者进行分层。   该研究为一项回顾性队列研究,旨在对非增生性视网膜病变(NPD

Diabetes Care:肾功能受损或与视网膜血流降低相关

  日本学者的一项研究表明,肾功能受损可能与视网膜血流(RBF)降低具有相关性。论文于2012年11月30日在线发表于《糖尿病护理》(Diabetes Care)杂志。   此项研究共纳入169例(169只眼)平均年龄为59岁的2型糖尿病患者;受试者无或伴轻微糖尿病视网膜病变,并且无或伴微量蛋白尿。通过同时测定视网膜血管直径和血流速度获取RBF。利用通过年龄和血清肌酐计算的估计肾小球滤

JDC:糖尿病视网膜病变为显性肾病显著危险因素

  西班牙学者的一项研究表明,1型糖尿病患者可形成仅伴糖尿病视网膜病变(DR)以及同时伴显性肾病(ON)和DR的两组人群;前者发病率随糖尿病持续时间延长而增加,后者发病率则与HbA1c水平显著相关。论文于2012年8月24日在线发表于《糖尿病及其并发症杂志》(J Diabetes Complications)。   此项前瞻性研究共纳入110例序贯性1型糖尿病患者,并进行了为期20年的随访。基线

杨金奎:糖尿病患者应分层筛查视网膜病变

在2013年中国医师协会内分泌代谢科医师分会年会(2013.7.4-7.6,吉林长春)上,首都医科大学附属北京同仁医院杨金奎教授指出,糖尿病视网膜病变是成人最常见的致盲原因。强化降糖治疗可以防止或延迟糖尿病视网膜病变的发生。 除了血糖,其他一些因素也会增加视网膜病变风险,高血压是黄斑水肿的危险因素,也与增殖期视网膜病变的发生相关。亚临床甲状腺功能减低与威胁视力的视网膜病变相关,妊娠会加重糖尿病视